57093-55-7

Basic information

• Product Name: Cyclohexaneacetic acid, a-cyano-1-methyl-, ethyl ester
• CAS NO: 57093-55-7
• Molecular Formula: C12H19NO2
• Molecular Weight: 209.288
• Mol File: 57093-55-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Cyclohexaneacetic acid, a-cyano-1-methyl-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexaneacetic acid, a-cyano-1-methyl-, ethyl ester(57093-55-7)
• EPA Substance Registry System: Cyclohexaneacetic acid, a-cyano-1-methyl-, ethyl ester(57093-55-7)

Safety Data

• Hazardous Substances Data: 57093-55-7(Hazardous Substances Data)

Upstream product

• 75-16-1 methylmagnesium bromide 
• 6802-76-2 ethyl 2-cyano-2-cyclohexylideneacetate 
• 108-94-1 cyclohexanone 
• 74-88-4 methyl iodide 
• 917-64-6 methyl magnesium iodide 
• 60-29-7 diethyl ether 

Downstream Products

• 82495-11-2 2-(1-methylcyclohexyl)ethanol 
• 79405-31-5 (1-methylcyclohexyl)acetaldehyde 
• 29668-55-1 (1-methylcyclohexyl)acetone 
• 20608-66-6 Methyl 1-methylcyclohexaneacetate 
• 78775-96-9 (1-Methylcyclohexyl)cyanessigsaeure-trimethylsilylester 
• 78775-78-7 (1-Methylcyclohexyl)cyanacetylchlorid 
• 57093-66-0 (1-Methylcyclohexyl)cyanessigsaeure 
• 14352-58-0 (1-methylcyclohexyl)acetic acid 
• 99062-31-4 (1-methylcyclohexyl)acetonitrile 

Relevant articles and documents

Distal γ-C(sp3)?H Olefination of Ketone Derivatives and Free Carboxylic Acids

Reported herein is the distal γ-C(sp3)?H olefination of ketone derivatives and free carboxylic acids. Fine tuning of a previously reported imino-acid directing group and using the ligand combination of a mono-N-protected amino acid (MPAA) and an electron-deficient 2-pyridone were critical for the γ-C(sp3)?H olefination of ketone substrates. In addition, MPAAs enabled the γ-C(sp3)?H olefination of free carboxylic acids to form diverse six-membered lactones. Besides alkyl carboxylic acids, benzylic C(sp3)?H bonds also could be functionalized to form 3,4-dihydroisocoumarin structures in a single step from 2-methyl benzoic acid derivatives. The utility of these protocols was demonstrated in large scale reactions and diversification of the γ-C(sp3)?H olefinated products.

HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS

The present invention relates to compounds of formula (I): wherein R1, R2, R4, n and m are as defined herein and R3 is selected from: (i) -C(O)OR31 wherein R31 is (C1-6)alkyl or aryl, wherein the (C1-6)alkyl is optionally substituted with one to three halogen substituents; (ii) -C(O)NR32R33, wherein R32 and R33 are each independently selected form H, (C1-6)alkyl, and Het; (iii) -SOvR34, wherein v is 1 or 2 and R34 is selected from: (C1-6)alkyl, aryl, Het, and NR32R33 wherein R32 and R33 are as defined above; and (iv) -CO(O)-R35, wherein R35 is selected from (C1-8)alkyl, (C3-7)cycloalkyl-(C1-4)alkyl, aryl, aryl-(C1-6)alkyl, Het and Het-(C1-6)alkyl, each of which are optionally substituted with one or more substituents each independently selected from halo, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, Het, hydroxyl, -O-(C1-6)alkyl, -S-(C1-6)alkyl, -SO-(C1-6)alkyl, -SO2-(C1-6)alkyl, -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl, wherein the aryl portion of the -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl are each optionally substituted with one to five halo substituents. The present invention further relates to pharmaceutical compositions containing the compounds of formula (I) and methods for using these analogs in the treatment of HCV infection.